Edmund Ingham

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.

Community Health Systems' revenues increased slightly, but operating income fell sharply. Learn why CYH stock may still hold potential despite recent declines.

GeneDx Holdings stock has surged over 3,000% in the past year with promising earnings and market potential, but growth may be limited. Click for more on WGS.

Besides the Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock valuation will fall over time. Read the full report here.

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Humana's stock has fallen over 30% due to rising healthcare utilization and CMS pushing back on insurer profits, impacting MA-focused companies. Read our updated analysis here.

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a long-term Buy rating for EBS stock.

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster therapies in its pipeline, providing "one and done" gene therapy cures.

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors. See my recommendation on IOVA stock.

BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if FDA greenlights the drug.